Page last updated: 2024-11-12

rg 7128

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine: inhibits HCV polymerase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16122663
CHEMBL ID562967
SCHEMBL ID811260
MeSH IDM0549873

Synonyms (47)

Synonym
HY-10240
rg 7128; mericitabine; psi 6130 diisobutyrate
R-7128,CAS:940908-79-2
rg-7128
mericitabine
r-4048
ro-5024048
r-7128
r7128 ,
3',5'-diisobutyryl psi 6130
CHEMBL562967
r 7128
rg 7128
ro5024048
psi 6130 diisobutyrate
2'-fluoro-2'-methyl-3',5'-diisobutyryldeoxycytidine
unii-ta63jx8x52
rg7128
cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, 3',5'-bis(2-methylpropanoate), (2'r)-
940908-79-2
mericitabine [usan:inn]
ta63jx8x52 ,
2'-deoxy-2'-fluoro-2'-c-methylcytidine diisobutyrate
mericitabine (usan/inn)
D10477
CS-0596
SCHEMBL811260
[(2r,3r,4r,5r)-5-(4-amino-2-oxo-pyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)tetrahydrofuran-2-yl]methyl 2-methylpropanoate
mericitabine [inn]
mericitabine [usan]
psi6130 diisobutyrate
3',5'-diisobutyryl psi6130
2'.alpha.-fluoro-2'.beta.-methyl-3',5'-diisobutyryldeoxycytidine
mericitabine [who-dd]
[(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-4-fluoro-4-methyl-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
AKOS027314064
EX-A5262
DB12045
BCP13789
Q21099044
rg 7128;r-7128;psi 6130 diisobutyrate
(2r,3r,4r,5r)-5-(4-amino-2-oxopyrimidin-1(2h)-yl)-4-fluoro-2-((isobutyryloxy)methyl)-4-methyltetrahydrofuran-3-yl isobutyrate ,
NCGC00379064-01
F84599
MS-26769
(2'r)- 2'-deoxy-2'-fluoro-2'-methylcytidine 3',5'-bis(2-methylpropanoate)
DTXSID201025655

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" To better understand the mechanism for adverse events, clinically relevant HCV NI were characterized in biochemical and cellular assays, including assays of decreased viability in multiple cell lines and primary cells, interaction with human DNA and RNA polymerases, and inhibition of mitochondrial protein synthesis and respiration."( Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus.
Ahmadyar, S; Babusis, D; Barauskas, O; Feng, JY; McCutcheon, K; Park, Y; Perron, M; Perry, JK; Ray, AS; Sakowicz, R; Schultz, BE; Stepan, G; Xu, Y; Yu, H, 2016
)
0.43

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetics were estimated by non-compartmental methods, and pharmacokinetic parameters of RO4995855 were normalized by body weight."( Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.
Chen, YC; Goelzer, P; Haznedar, J; Moreira, S; Washington, C, 2014
)
0.4

Compound-Compound Interactions

ExcerptReferenceRelevance
"7 and 5 log(10) IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks."( RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM, 2010
)
0.36
" From 85 patients receiving RG7128 in combination with SOC, 1 HCV genotype 1-infected patient experienced a viral rebound, and 2 genotype 3-infected patients experienced a transient rebound."( RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM, 2010
)
0.36
"Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (<2-log10 reduction in HCV RNA by treatment week 12) to peginterferon/ribavirin (PegIFN/RBV) do not achieve a sustained virological response (SVR) when re-treated with a first-generation HCV protease inhibitor (PI) administered in combination with PegIFN/RBV."( Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H, 2016
)
0.43

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Our SAR studies ultimately led to compounds that gave high levels of NTP in hamster and rat liver after subcutaneous dosing and that were devoid of the toxic phenol moiety usually found in ProTides."( Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
Attenni, B; Di Marco, A; Donghi, M; Fiore, F; Gardelli, C; Gennari, N; Giuliano, C; Harper, S; Laufer, R; Leone, JF; MacCoss, M; Marcucci, I; Meppen, M; Narjes, F; Olsen, DB; Pacini, B; Pucci, V; Rowley, M, 2009
)
0.35
" However, the pharmacist who prepared the doses, personnel involved in pharmacokinetic sample analyses, statisticians who prepared data summaries, and the clinical pharmacologists who reviewed the data before deciding to initiate dosing in the next cohort were not masked to treatment allocation."( Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial.
Angus, PW; Baher, L; Berrey, MM; Bradford, W; Chu, T; Elston, R; Gane, EJ; Ipe, D; Laughlin, M; Lopatin, U; Morcos, PN; Najera, I; Ritchie, B; Roberts, SK; Shulman, NS; Smith, PF; Stedman, CA, 2010
)
0.36
" ε(2) was high with bid dosing (mean 750 mg and 1500 mg: 98."( Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128).
Dahari, H; Guedj, J; Perelson, AS; Shudo, E; Smith, P, 2012
)
0.38
" Treatment-naïve HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E)."( PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients.
Bzowej, N; Chen, YC; Ferenci, P; Herring, R; Ipe, D; Jensen, D; Ma, MM; Munson, ML; Najera, I; Pockros, P; Rodriguez-Torres, M; Thommes, J; Vierling, J; Wedemeyer, H; Zeuzem, S, 2013
)
0.39
" The results support the use of the same dosing regimens in Caucasian and Asian subjects."( Single-dose pharmacokinetics of the HCV polymerase inhibitor mericitabine in healthy Caucasian and Japanese subjects.
Chen, YC; Goelzer, P; Haznedar, J; Moreira, S; Washington, C, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID431929Antiviral activity against HCV assessed as logarithmic reduction in plasma viral RNA at 1500 mg, po BID after 14 days2009Journal of medicinal chemistry, Sep-10, Volume: 52, Issue:17
Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
AID546828Cytotoxicity against human HuH7 cells2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938.
AID1441830Cytotoxicity against human HuH7 cells2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Synthesis and Cytostatic and Antiviral Profiling of Thieno-Fused 7-Deazapurine Ribonucleosides.
AID1445764Inhibition of wild type NS5B in HCV genotype 1b replicon expressed in human HuH7 cells after 72 hrs by bright Glo-luciferase reporter gene assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID1445765Cytotoxicity against human HuH7 cells assessed as reduction in cell viability up to 100 uM after 72 hrs by Cell Titer-Fluor Cell assay2017Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14
Discovery of Novel Nucleotide Prodrugs with Improved Potency Against HCV Variants Carrying NS5B S282T Mutation.
AID762838Antiviral activity against HCV infected in human Huh7 cells assessed as inhibition of viral replication by measuring EGFP autofluorescence at 2 uM by CCK8 assay relative to control2013Bioorganic & medicinal chemistry letters, Aug-15, Volume: 23, Issue:16
Tetrazole and triazole as bioisosteres of carboxylic acid: discovery of diketo tetrazoles and diketo triazoles as anti-HCV agents.
AID1416668Antiviral activity against HCV genotype 2a infected in human Hep2 replicon cells after 3 days by luciferase reporter gene assay2017MedChemComm, Sep-01, Volume: 8, Issue:9
Sugar modified pyrimido[4,5-
AID1533371Antiviral activity against Hepatitis C virus genotype 1b infected in human Huh-luc replicon cells after 3 days by luciferase assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides.
AID517732Antiviral activity against HCV infected in human clone A cells assessed as inhibition of cellular rRNA replication at 50 uM2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1533372Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by CellTiter-Glo assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides.
AID1416669Antiviral activity against HCV genotype 1b infected in human Hep2 replicon cells after 3 days by luciferase reporter gene assay2017MedChemComm, Sep-01, Volume: 8, Issue:9
Sugar modified pyrimido[4,5-
AID546827Antiviral activity against Hepatitis C virus -infected in human HuH7 cells2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug analogs as inhibitors of HCV NS5B polymerase: discovery of PSI-352938.
AID517723Antiviral activity against HCV infected in human clone A cells2010Journal of medicinal chemistry, Oct-14, Volume: 53, Issue:19
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.
AID1533373Antiviral activity against Hepatitis C virus genotype 2a infected in human Huh-luc replicon cells after 3 days by luciferase assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Synthesis and Cytotoxic and Antiviral Profiling of Pyrrolo- and Furo-Fused 7-Deazapurine Ribonucleosides.
AID1416667Cytotoxicity against human Hep2 cells2017MedChemComm, Sep-01, Volume: 8, Issue:9
Sugar modified pyrimido[4,5-
AID1441775Anti-HCV activity against Hepatitis C virus genotype 2a infected in human Huh7 replicon cells after 96 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Synthesis and Cytostatic and Antiviral Profiling of Thieno-Fused 7-Deazapurine Ribonucleosides.
AID1416677Selectivity index, ratio of CC50 for human Hep2 cells to EC50 for HCV 1b infected in human Hep2 replicon cells2017MedChemComm, Sep-01, Volume: 8, Issue:9
Sugar modified pyrimido[4,5-
AID1416678Selectivity index, ratio of CC50 for human Hep2 cells to EC50 for HCV 2a infected in human Hep2 replicon cells2017MedChemComm, Sep-01, Volume: 8, Issue:9
Sugar modified pyrimido[4,5-
AID1441774Anti-HCV activity against Hepatitis C virus genotype 1b infected in human Huh7 replicon cells after 96 hrs by luciferase reporter gene assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Synthesis and Cytostatic and Antiviral Profiling of Thieno-Fused 7-Deazapurine Ribonucleosides.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (41)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (2.44)29.6817
2010's39 (95.12)24.3611
2020's1 (2.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.99 (24.57)
Research Supply Index4.09 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials17 (40.48%)5.53%
Reviews7 (16.67%)6.00%
Case Studies1 (2.38%)4.05%
Observational0 (0.00%)0.25%
Other17 (40.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]